Histogen (HSTO) Competitors $0.0003 0.00 (0.00%) As of 07/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock HSTO vs. HEPA, BPTSY, VRPX, VIRX, NCNA, BON, CAPS, MYMD, VINC, and UPCShould you be buying Histogen stock or one of its competitors? The main competitors of Histogen include Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Virpax Pharmaceuticals (VRPX), Viracta Therapeutics (VIRX), NuCana (NCNA), Bon Natural Life (BON), Capstone Therapeutics (CAPS), MyMD Pharmaceuticals (MYMD), Vincerx Pharma (VINC), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical products" industry. Histogen vs. Its Competitors Hepion Pharmaceuticals Biophytis Virpax Pharmaceuticals Viracta Therapeutics NuCana Bon Natural Life Capstone Therapeutics MyMD Pharmaceuticals Vincerx Pharma Universe Pharmaceuticals Histogen (NASDAQ:HSTO) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Do insiders and institutionals believe in HSTO or HEPA? 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 3.3% of Histogen shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, HSTO or HEPA? Histogen has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Is HSTO or HEPA more profitable? Histogen's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets HistogenN/A N/A N/A Hepion Pharmaceuticals N/A -812.56%-207.31% Does the media favor HSTO or HEPA? In the previous week, Histogen's average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score. Company Overall Sentiment Histogen Neutral Hepion Pharmaceuticals Neutral Which has preferable valuation and earnings, HSTO or HEPA? Histogen has higher revenue and earnings than Hepion Pharmaceuticals. Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Histogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHistogen$19K0.07-$10.62M-$2.810.00Hepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 SummaryHistogen beats Hepion Pharmaceuticals on 7 of the 9 factors compared between the two stocks. Get Histogen News Delivered to You Automatically Sign up to receive the latest news and ratings for HSTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HSTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HSTO vs. The Competition Export to ExcelMetricHistogenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$776.92M$5.70B$9.50BDividend YieldN/A4.84%4.60%4.01%P/E Ratio0.001.4028.1020.05Price / Sales0.0725.35429.3789.38Price / CashN/A19.5636.2258.56Price / Book0.006.798.665.87Net Income-$10.62M-$4.32M$3.25B$258.55M7 Day PerformanceN/A1.15%4.22%3.73%1 Month PerformanceN/A3.76%10.51%11.75%1 Year PerformanceN/A9.52%34.40%18.03% Histogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020HEPAHepion Pharmaceuticals0.1279 of 5 stars$0.05-6.4%N/A-99.9%$528KN/A-0.0120Gap UpBPTSYBiophytisN/A$1.33-8.3%N/AN/A$467KN/A0.0030Gap DownVRPXVirpax PharmaceuticalsN/A$0.36-2.5%$75.00+20,675.6%-99.9%$448KN/A0.007Gap DownVIRXViracta Therapeutics2.567 of 5 stars$0.01-5.0%$1.75+18,129.2%N/A$382KN/A-0.0120High Trading VolumeNCNANuCana3.3263 of 5 stars$0.05+9.4%$25.00+49,700.8%-98.3%$280KN/A-0.0130Gap UpHigh Trading VolumeBONBon Natural Life0.6411 of 5 stars$1.48-3.3%N/AN/A$260K$23.84M0.00100Gap UpCAPSCapstone TherapeuticsN/A$1.51-5.0%N/AN/A$251K$43.42M0.0038MYMDMyMD PharmaceuticalsN/A$0.10-6.3%N/A-92.9%$242KN/A0.006Gap DownHigh Trading VolumeVINCVincerx Pharma2.4883 of 5 stars$0.04-7.5%$40.00+92,923.3%-99.6%$225KN/A0.0060Gap UpUPCUniverse PharmaceuticalsN/A$3.72-2.9%N/A-99.8%$160K$19.29M0.00220 Related Companies and Tools Related Companies Hepion Pharmaceuticals Competitors Biophytis Competitors Virpax Pharmaceuticals Competitors Viracta Therapeutics Competitors NuCana Competitors Bon Natural Life Competitors Capstone Therapeutics Competitors MyMD Pharmaceuticals Competitors Vincerx Pharma Competitors Universe Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HSTO) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.